- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing klebsiella pneumoniaein patients on maintenance hemodialysis
© Yang et al.; licensee BioMed Central Ltd. 2012
Received: 29 July 2011
Accepted: 31 August 2012
Published: 5 September 2012
Hemodialysis (HD) patients are susceptible to extended spectrum beta-lactamase (ESBL)-producing bacterial infections. Because the optimal treatment and clinical significance of ESBL-producing Klebsiella pneumoniae (ESBL-Kp) HD access-related bacteremia remain unclear, we conducted this retrospective study to determine the clinical outcomes of patients treated with either flomoxef or a carbapenem.
The eligibility criterion was fistula or graft- or catheter- related ESBL-Kp bacteremia in patients on maintenance HD. The clinical characteristics and antibiotic management were analyzed. Outcome was determined by mortality resulting from bacteremia during the 14‐day period after the first positive blood culture for flomoxef-susceptible ESBL-Kp.
The 57 patients studied were predominantly elderly, malnourished, with a history of severe illnesses and broad-spectrum antibiotic use before the onset of bacteremia, and with severe septicemia as determined by the Pitt bacteremia score (PBS). The study population comprised 7 fistula, 8 graft, and 42 HD catheter-related bacteremia (CRB) cases, and the mortality rate was high (36/57, 63.2%) in these 57 patients. Of 42 patients with CRB, those in the deceased group (27/42, 64.3%) had significantly lower levels of serum albumin, longer prior hospital stay and duration of catheter-dependent HD, and higher PBS than patients in the survived group. Failure to receive effective antibiotics (flomoxef or a carbapenem) within 5 days after onset of bacteremia and treatment with flomoxef both significantly contributed to higher mortality. Multivariate analyses revealed that flomoxef use, PBS, and catheter-dependent HD >30 days were independently associated with increased mortality (OR, 3.52; 95% CI, 1.19–58.17, OR, 2.92; 95% CI, 1.36–6.26 and OR, 5.73; 95% CI, 1.21–63.2, respectively).
Considering the high mortality rate, ESBL-Kp should be recognized as a possible pathogen in patients on maintenance HD at high risk of acquiring HD access infections associated with ESBL-producing bacteria. Carbapenems rather than flomoxef should be the therapy of choice in these critically vulnerable patients.
Hemodialysis (HD) access-related infections are a major cause of morbidity and mortality in HD patients; the responsible microorganisms, prevention and treatment strategies, and outcome have been assessed in earlier studies [1, 2]. Gram-negative bacteria (GNB) have been reported in up to 33% of cases with catheter-related bacteremia (CRB), indicating that empiric antibiotic therapy should target both gram-positive and gram-negative organisms . Ignoring the possibility of GNB, especially those producing extended spectrum beta-lactamase (ESBL), as mediators of HD access-related infections places a considerable number of patients at unwarranted risk.
Risk factors for the acquisition of ESBL infections have been well studied and include—but are not limited to—HD, old age, prolonged hospitalization, severe illness, poor nutritional status, treatment in an intensive care unit (ICU), and previous exposure to broad-spectrum antibiotics, with overuse of extended-spectrum cephalosporins in the hospital setting as one of the most important factors [3, 4]. In addition to the risk of immunocompromise, HD patients may be rendered susceptible to ESBL-related infection by frequent vascular catheterization, catheter manipulation, and the need for broad-spectrum antibiotics during prolonged hospitalization, especially in the ICU setting.
The currently recommended therapy for infection caused by ESBL-producing organisms consists of carbapenems [4, 5]. Cephamycins (i.e., cefmetazole, cefotetan, and flomoxef), characterized by their 7-α-methyoxy β-lactam, have been reported to be highly active in vitro against both low inocula (105–106 cfu/mL) and high inocula (107–108 cfu/mL) of TEM- or SHV-producing Enterobacteriaceae . Unfortunately, the use of cephamycins is not universal but limited in some countries. In addition, many controversies about optimal treatment exist, and few clinical reports comparing the treatment efficacy of cephamycins and carbapenems have been published .
The vast majority of Klebsiella pneumoniae (K. pneumoniae) infections are associated with hospitalization, and ESBL-producing bacteria are reported to comprise a significant percentage of nosocomial K. pneumoniae strains . In a retrospective study, treatment with either flomoxef or a carbapenem in patients with flomoxef-susceptible ESBL-producing K. pneumoniae (ESBL-Kp) bacteremia was reported to be similarly effective . However, their clinical effectiveness and most appropriate antibiotic prescription strategies for HD access-related ESBL-Kp bacteremia in patients on maintenance HD (MHD) have not yet been established. We conducted this 7-year retrospective study to compare the clinical outcomes of patients treated with either flomoxef or a carbapenem, and to gain a better understanding of the clinical significance and impact of HD access-related ESBL-Kp bacteremia in patients on MHD.
Study population and design
This retrospective study was conducted in a tertiary care hospital with 950 MHD patients treated in the outpatient department. MHD patients admitted during the 7-year period from January 2001 to December 2007 who developed a nosocomial HD access-related infection secondary to ESBL-Kp were included. The eligibility criterion was HD access, including arteriovenous fistula or graft- or catheter-related ESBL-Kp bacteremia. Only adult patients with flomoxef-susceptible ESBL-Kp bacteremia who were treated with either flomoxef or a carbapenem (meropenem or imipenem) were included. For each included patient, the prescribed flomoxef or a carbapenem was administered for at least 2 days, starting within 5 days after receiving finalized blood culture results. The use of either flomoxef or a carbapenem was left to the discretion of the attending physician in each case. Details of the patients’ clinical course, biochemical data, sites of ESBL-Kp infection (blood, HD catheter tip, pus from HD catheter exit site, and pus from fistula or graft wounds), and outcome were obtained from medical charts. Individual patient without blood culture that grew ESBL-Kp was excluded because, in the absence of concurrent blood cultures from the peripheral vein, there is a risk of enrolling patients simply representing colonization. Severely ill patients who died rapidly without receiving a carbapenem or flomoxef for at least two days were also excluded. Variables used for the assessment of severity of illness included Pitt bacteremia score (PBS), ICU stay at the time of bacteremia, and length of prior hospital stay (LOS). Mortality resulting from bacteremia within 14 days after the first positive blood culture that grew flomoxef-susceptible ESBL-Kp was used to determine the outcome.
The study was approved by the institutional review board of Kaohsiung Chang Gung Memorial Hospital with the study ID: CGMH-IRB-100-2452B.
All K. pneumoniae isolates were identified by standard methods, and the presence of ESBLs was evaluated using the Clinical and Laboratory Standards Institute criteria for ESBL screening and disc confirmation test . Minimum inhibitory concentrations (MICs) ≤ 4 mg/L for meropenem and ≤ 8 mg/L for flomoxef were considered to indicate susceptibility [11, 12].
ESBL-Kp bacteremia was defined by the isolation of ESBL-Kp from blood cultures. Nosocomial bacteremia was defined as bacteremia occurring >48 h after admission to the hospital. HD access infections were defined as local signs (pus or redness) at the vascular access site with or without a positive culture of catheter tip, pus, or a positive blood culture with no known source other than the vascular access. Empiric antibiotic was defined as antibiotic therapy started at the time blood cultures were drawn. Effective antibiotics for flomoxef-susceptible ESBL-Kp bacteremia included carbapenems and flomoxef. Significant underlying disease was defined as a medical history of diabetes mellitus, liver cirrhosis, malignancy, and congestive heart failure.
All statistical analyses were performed using the Statistical Package for Social Science program (SPSS for Windows, Version 11.5; SPSS, Chicago, IL). Continuous variables were each expressed as the mean ± SD and were analyzed using the Student t test. The statistical difference in the frequency of occurrence of the variants in patients with HD catheter-related bacteremia between survived and deceased subgroups was assessed by the chi-square test or Fisher’s exact test. A logistic regression model was used to estimate the effects of multiple factors associated with mortality in the univariate analyses. Variables with P ≤ 0.1 in univariate analysis between patients of deceased and survived groups were entered for further assessment. Estimated ORs and 95% CI were obtained from this model. For all analyses, two-sided tests of significance were used with P < 0.05 considered significant.
Comparisons of demographic and clinical data between the groups of different HD access related ESBL-Kp bacteremia
Source of infection
64.8 ± 10.0
61 ± 10.5
65.1 ± 7.8
64.4 ± 9.5
Patients aged >65 years (%)
Admission for infectious diseases (%)
Significant underlying diseases (%)
Congestive heart failure
Comorbid conditions (%)
Poor nutrition a
Prior antibiotic use b
Previous severe illness c
Prolonged (>30 days) hospitalization
Prior use of 3rd-generation cephalosporin
ICU stay at or after the onset of bacteremia
Pitt bacteremia score
5.29 ± 1.67
5 ± 1.73
6.38 ± 2.26
5.4 ± 1.78
ABx after onset of bacteremia d
Effective ABx within 5 days (%)
Use flomoxef/IMP /MEP as effective ABx(%)
6 (75)/none/ 2(25)
In addition to antibiotic treatment, surgical interventions (wound debridement and/or removal of infected fistula or graft) were performed in 7 of 15 patients with fistula or graft infection. All HD catheters related to ESBL-Kp bacteremia in 42 patients were removed after the onset of bacteremia. The extent and perioperative risk of surgery may affect survival of patients with fistula or graft infection but their effects were difficult to estimate. We believe bias and confounding factors could be reduced if we only analyzed 42 patients, all with catheter-related bacteremia.
Comparisons of demographic and clinical data between the deceased and survived groups of the 42 patients with CRB; Variables with a p -value < 0.1 by univariate analysis were subjected to multivariate analysis
n = 15
n = 27
n = 42
Mean age, years
63.2 ± 7.6
65.7 ± 10.3
64.8 ± 10.0
Patients aged >65 years (%)
Flomoxef treatment (%) a
Treatment within 5 days
Pitt bacteremia score, mean ± SD a
4.27 ± 1.03
5.85 ± 1.7
5.29 ± 1.67
Serum albumin(g/dL), mean ± SD
2.70 ± 0.31
2.12 ± 0.42
2.33 ± 0.61
Hemoglobin(g/dL), mean ± SD
8.98 ± 0.71
9.13 ± 1.92
9.08 ± 1.56
Hospital days before onset, mean ± SD
49 ± 35.8
116.9 ± 87.5
92.6 ± 79.6
No. of hospital days before onset > 30 (%)
Duration of catheter-dependent HD(days)
24.5 ± 9.2
43.6 ± 12.3
36.6 ± 10.2
No. of catheter-dependent HD days > 30 (%) a
ICU stay at the time of bacteremia
Variables that were determined to be significantly associated with mortality at 14 days after the first positive blood culture result by univariate analysis were subjected to multivariate analysis. Flomoxef use, higher PBS, and catheter-dependent HD > 30 days were independently associated with increased mortality (OR, 3.52; 95% CI, 1.19–58.17; OR, 2.92; 95% CI, 1.36–6.26 and OR, 5.73; 95% CI, 1.21–63.2, respectively).
There is limited information regarding the clinical characteristics associated with HD access-related ESBL-Kp bacteremia in MHD patients. Most of the patients with bacteremia in the present study were elderly, malnourished, and had a history of severe illness and prolonged hospitalization. These patients were also critically ill, as determined by PBS, and had high prevalence rates of significant underlying diseases and ICU stay at the time of the onset of bacteremia; therefore, they had a high mortality rate(36/57, 63.2%). Although broad-spectrum antibiotic treatment prior to the onset of bacteremia was also highly prevalent, its contribution to the acquisition of ESBL infection and effect on patient outcome were not analyzed; this might contribute to an epidemiological bias. Only 36.8% of these critically ill patients received empiric effective antibiotics within 5 days after the first positive blood culture for ESBL-Kp, which may have contributed to the high mortality rate.
Previous studies have demonstrated vascular access accounts for 48–73% of bacteremia in HD patients . In the present study, both longer LOS and a lower serum albumin level were associated with high mortality in patients with CRB. Prolonged hospitalization has been recognized as a risk factor for ESBL infection in prior studies, which reported a mean time to acquisition of ESBL-Kp bacteremia of more than 1 month . Hypoalbuminemia was found to increase the likelihood of a recurrent episode of CRB among patients treated for an initial CRB . In the present study, the duration of catheter-dependent HD before bacteremia was on an average longer than 1 month, and catheter-dependent HD ≥ 30 days was a significant independent risk factor for increased mortality by multivariate analysis. These findings suggest that shortening the duration of catheter-dependent HD may decrease the probability of CRB secondary to ESBL-producing bacteria and improve the prognosis. It is not surprising to find that higher PBS was independently associated with increased mortality. There was also a trend toward a longer ICU stay at the time of bacteremia in the deceased group. Because MHD patients with HD access-related ESBL-Kp bacteremia were mostly immunocompromised and critically ill, their mortality rate was determined by these parameters, which reflected the severity of the septicemia.
For ESBL infections, there are both a higher clinical failure rate  and mortality rate  associated with cephalosporin treatment. Furthermore, ESBL-producing bacteria are frequently resistant to many classes of beta-lactam and non-beta-lactam antibiotics, including cefepime , beta-lactam/beta-lactamase inhibitor combinations, fluoroquinolones , and aminoglycosides . The emergence of multi-drug resistance in these virulent pathogens has significantly hampered the effort to devise effective empiric or directed antibiotic treatment regimens, and is associated with high treatment failure rates. Unfortunately, most of our patients initially received ineffective empiric antibiotics, including extended-spectrum cephalosporins, which increased the difficulty of further treatment and led to a high treatment failure and mortality rates.
Although carbapenems have been recommended for the treatment of infections caused by ESBL-producing organisms, extensive use of these antibiotics may result in the outbreak of infections related to carbapenem-resistant strains such as Acinetobacter baumanii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia, and it poses challenging infection-control issues. Flomoxef is unique among cephamycins in having a difluoromethylthio-acetamido group at position 7, which improves its in vitro activity against ESBL-producing Enterobacteriaceae [6, 21]. Flomoxef was also shown to be as clinically effective as a carbapenem for the treatment of flomoxef-susceptible ESBL-Kp bacteremia in terms of clinical outcome and comparable results of time-kill studies regardless of the inoculum size of 105 or 107 cfu/mL . Although this study was limited by its retrospective design and small sample size, it provides insight into the possibility of using a cephamycin for infections caused by ESBL-producing bacteria. However, the efficacy of these agents for the treatment of HD access-related ESBL-Kp bacteremia in MHD patients is still unclear.
The use of effective antibiotics such as carbapenems during the 5-day period after the onset of bacteremia due to an ESBL-producing organism has been reported to be associated with lower mortality . In the present study, treatment with effective antibiotics within 5 days after the onset of bacteremia and the use of carbapenems improved the prognosis in patients with CRB. The choice of antibiotics is critical, in the light of our finding that treatment with flomoxef was an independent risk factor for increased mortality in these vulnerable patients by multivariate analyses. The lower percentage of patients receiving effective empiric antibiotics may reflect our collective unawareness of the significance of these emerging strains and the very limited information regarding this issue.
This is the first study to report the clinical implications of nosocomial HD access-related ESBL-Kp bacteremia. We stress that ESBL-Kp should be considered as a possible pathogen in HD access-related infections. Because of the high antimicrobial resistance and high mortality rate in these more vulnerable and critically ill patients, we suggest carbapenems rather than flomoxef as the first choice for empiric or directed therapy in HD patients at high risk for HD access-related ESBL-Kp infections. Shortening the duration of catheter-dependent HD also improved the outcome.
- Allon M: Dialysis catheter-related bacteraemia: treatment and prophylaxis. Am J Kidney Dis. 2004, 44: 779-791.View ArticlePubMedGoogle Scholar
- Nassar GM, Ayus JC: Infectious complications of the hemodialysis access. Kidney Int. 2001, 60: 1-13. 10.1046/j.1523-1755.2001.00765.x.View ArticlePubMedGoogle Scholar
- Bradford PA: Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001, 14: 933-951. 10.1128/CMR.14.4.933-951.2001.View ArticlePubMedPubMed CentralGoogle Scholar
- Rupp ME, Fey PD: Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs. 2003, 63: 353-365. 10.2165/00003495-200363040-00002.View ArticlePubMedGoogle Scholar
- Paterson DL: Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect. 2000, 6: 460-463. 10.1046/j.1469-0691.2000.00107.x.View ArticlePubMedGoogle Scholar
- Jacoby GA, Carreras I: Activities of beta-lactam antibiotics against Escherichia coli strains producing extended spectrumβ-lactamases. Antimicrob Agents Chemother. 1990, 34: 858-862. 10.1128/AAC.34.5.858.View ArticlePubMedPubMed CentralGoogle Scholar
- Pitout JD, Laupland KB: Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008, 8: 159-166. 10.1016/S1473-3099(08)70041-0.View ArticlePubMedGoogle Scholar
- Yan JJ, Wu SM, Tsai SH, Wu JJ, Su IJ: Prevalence of SHV-12 among clinical isolates of Klebsiella pneumoniae producing extended-spectrum beta-lactamases and identification of a novel AmpC enzyme (CMY-8) in Southern Taiwan. Antimicrob Agents Chemother. 2000, 44: 1438-1442. 10.1128/AAC.44.6.1438-1442.2000.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee CH, Su LH, Tang YF, Liu JW: Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother. 2006, 58: 1074-1077. 10.1093/jac/dkl381.View ArticlePubMedGoogle Scholar
- Paterson DL, Bonomo RA: Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005, 18: 657-686. 10.1128/CMR.18.4.657-686.2005.View ArticlePubMedPubMed CentralGoogle Scholar
- National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing—Eleventh Informational Supplements: Approved Standard M100-S10. 2001, NCCLS, Villanova, PA, USAGoogle Scholar
- Grimm H: Interpretive criteria of antimicrobial disk susceptibility tests with flomoxef. Infection. 1991, 19 (Suppl 5): S258-263.View ArticlePubMedGoogle Scholar
- Kim BN, Woo JH, Kim MN, Ryu J, Kim YS: Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteremia. J Hosp Infect. 2002, 52: 99-106. 10.1053/jhin.2002.1288.View ArticlePubMedGoogle Scholar
- Paterson DL, Ko WC, Von Gottberg A, et al: Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001, 39: 2206-2212. 10.1128/JCM.39.6.2206-2212.2001.View ArticlePubMedPubMed CentralGoogle Scholar
- Thomson KS, Moland ES: Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2001, 45: 3548-3554. 10.1128/AAC.45.12.3548-3554.2001.View ArticlePubMedPubMed CentralGoogle Scholar
- Paterson DL, Mulazimoglu L, Casellas JM, et al: Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis. 2000, 30: 473-478. 10.1086/313719.View ArticlePubMedGoogle Scholar
- Jacoby GA, Sutton L: Properties of plasmids responsible for production of extended-spectrum β-lactamases. Antimicrob Agents Chemother. 1991, 35: 164-169. 10.1128/AAC.35.1.164.View ArticlePubMedPubMed CentralGoogle Scholar
- Go ES, Urban C, Burns J, et al: Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet. 1994, 344: 1329-1332. 10.1016/S0140-6736(94)90694-7.View ArticlePubMedGoogle Scholar
- Rahal JJ, Urban C, Horn D, et al: Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 1998, 280: 1233-1237. 10.1001/jama.280.14.1233.View ArticlePubMedGoogle Scholar
- Sanyal SC, Mokaddas EM: The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother. 1999, 11: 28-33.View ArticlePubMedGoogle Scholar
- Bauernfeind A, Schweighart S, Eberlein E, Jungwirth R: In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin). Infection. 1991, 19 (Suppl 5): 264-275.View ArticleGoogle Scholar
- Paterson DL, Ko WC, Von Gottberg A, et al: Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004, 39: 31-37. 10.1086/420816.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/12/206/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.